Amyotrophic lateral sclerosis, or ALS, is an uncommon neurological disorder that mainly affects the nerve cells that control voluntary muscle movements. The voluntary muscles are responsible for producing movements that include walking, chewing, and talking. This disease is very progressive, which means that symptoms get worse over time.
ALS is categorized to a group of disorders or diseases associated to motor neuron disorders, which are caused by the gradual weakening (degeneration) and expiry of motor neurons. The motor neurons are basically the nerve cells which extend from the brain to the brain, spinal cord and muscles throughout the body. These neurons of degenerate activity stop sending messages to the muscles, and the muscle gradually weakens and begins to contract and contract (atrophy). Moreover by the time, brain loses further its ability to initiate & control the intended movements. Once the motor neurons degenerate, they further stop transferring the messages to muscles, and muscles also gradually weaken, starts to contract & contract (atrophy). Generally, the first symptoms of ALS are muscle weakness or stiffness. There is not a single test that gives a definitive diagnosis of ALS. A neurological exam at the customary intervals can determine if symptoms such as muscle weakness, atrophy, and spasticity are worsening. Although most cases of ALS are irregular, meaning there is no family antiquity of the disease, about 10 % of cases are familial.
Referring to study, “Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Country: Trend Outlook and Growth Opportunity” some of the key enterprises that are very active in the Asia-Pacific ALS treatment market include Biohaven Pharmaceutical Holding Co., Ltd., F.Hoffmann-La Roche AG, Sun Pharmaceutical Industries Ltd., AB Science SA, BrainStorm Cell Limited, Otsuka Pharmaceutical Co., Ltd., Amylyx Pharmaceuticals Inc., Ionis Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corporation, Corestem, Inc., Biogen Inc. and among others. Leading players of the ALS treatment market are making immense investments in the R&D of new drugs & therapies. Continuous efforts by market participants to develop new drugs and treatments are driving the growth of the Asia-Pacific amyotrophic lateral sclerosis treatment market.
At present, there is no cure for Amyotrophic Lateral Sclerosis (ALS), and treatments such as drugs and stem cell therapy can only help to slow-down the disease progression, prevent unnecessary complications and manage the symptoms. In addition, the tendency towards a sedentary lifestyle among the geriatric population increases the risk of developing the disorder, increasing the need for targeted treatment options and new therapies.
The Asia-Pacific region is predicted to grow at a faster rate due to the high prevalence of ALS diseases and large number of surgical procedures across the region. It is predicted that future of the Asia Pacific Amyotrophic Lateral Sclerosis (ALS) treatment market will be optimistic on account of improving healthcare infrastructure coupled with rise in disposable income during the forecast period.
For More Information, click on the link below:-
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Region: Trend Outlook and Growth Opportunity
Ankur Gupta, Head Marketing & Communications